Document Detail

Cerebral interstitial levels of glutamate and glutamine after intravenous administration of nutritional amino acids in neurointensive care patients.
MedLine Citation:
PMID:  15893876     Owner:  NLM     Status:  MEDLINE    
After severe trauma or disease glutamine (GLN) is mobilised from all muscles, including the heart and smooth muscles. The result is weakness and fatigue which affects recovery. The breakdown of muscle tissue can be counteracted by external GLN supply. There are concerns, however, that increasing the blood glutamine (Blood-GLN) concentration in patients with acute brain diseases is harmful by elevating the CNS interstitial (IS) concentration of glutamate (CNS-GLT), and that this may result in a secondary excitotoxic injury. We therefore studied the IS CNS-GLN and CNS-GLT when a commercially available nutritional amino acid solution was given intravenously. Ten NICU patients were included. The IS concentrations of amino acids in the brain were measured using intracerebral microdialysis. Blood concentrations of amino acids were measured before and after the amino acid infusion. The change in Blood-GLN was 2.14 (median; range 1.34-3.22) times the basal levels and Blood-GLT increased 1.37 (median; range 0.93-3.45) times basal levels. Both changes were statistically significant. The changes in CNS-GLN was 1.21 (median; range 0.72-1.92) and for CNS-GLT 0.96 (median; range 0.45-1.53) times the basal levels. This was statistically significant for CNS-GLN but not for CNS-GLT. A high initial CNS-GLT (55.3 micromol/l) in one patient increased even further to 84.4 micromol/l after infusion of amino acid solution. We submit that nutritional amino acid solutions can be administrated to some patients with acute brain disease without increasing the CNS-GLT values. However, since BBB function was not quantified in our study, further evaluation of this issue is warranted.
Elisabeth Ronne Engström; Lars Hillered; Per Enblad; Torbjörn Karlsson
Related Documents :
25447846 - Alcohol disrupts levels and function of the cystic fibrosis transmembraneconductance re...
7320736 - Isolation and preliminary characterization of novel polysialogangliosides from embryoni...
1679206 - Changes in free amino acid concentrations in serum, brain, and csf throughout embryogen...
21191766 - Ph-independent sustained release matrix tablet containing doxazosin mesylate: effect of...
12064746 - Egyptian propolis: 3. antioxidant, antimicrobial activities and chemical composition of...
3227896 - Acid in proximal and distal duodenum inhibits, but hyperosmolal solution does not inhib...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Neuroscience letters     Volume:  384     ISSN:  0304-3940     ISO Abbreviation:  Neurosci. Lett.     Publication Date:    2005 Aug 12-19
Date Detail:
Created Date:  2005-06-20     Completed Date:  2005-08-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7600130     Medline TA:  Neurosci Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  7-10     Citation Subset:  IM    
Department of Neurosurgery, Uppsala University Hospital, 751 85 Uppsala, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acids / administration & dosage*
Brain Diseases / metabolism*,  therapy
Cerebral Cortex / drug effects*,  metabolism
Extracellular Space / drug effects*,  metabolism
Glutamic Acid / metabolism*
Glutamine / metabolism*
Infusions, Intravenous / methods
Intensive Care
Microdialysis / methods
Middle Aged
Reg. No./Substance:
0/Amino Acids; 56-85-9/Glutamine; 56-86-0/Glutamic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells.
Next Document:  When word category information encounters morphosyntax: an ERP study.